Recombinant Human TDGF1/Cripto Protein
Beta LifeScience
SKU/CAT #: BLK-00419P-100UG

Human TDGF1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human TDGF1/Cripto Protein
Beta LifeScience
SKU/CAT #: BLK-00419P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human TDGF1/Cripto Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu31-Thr172. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | P13385 |
Target Symbol | TDGF1/Cripto |
Species | Human |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Leu31-Thr172 |
Mol. Weight | The protein has a predicted MW of 16.92 kDa. Due to glycosylation, the protein migrates to 23-30 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | TDGF1 (CRIPTO) is a member of the epidermal growth factor-Cripto-1/FRL-1/Cryptic (EGF/CFC) gene family and an obligate co-receptor involved in NODAL signaling, a developmental program implicated in midline, forebrain, and left-right axis development in model organisms. Cripto-1 is enriched in a subpopulation of embryonal, melanoma, prostate, and pancreatic cancer cells that possess stem-like characteristics. Therefore, Cripto-1 may play a role during developmental EMT, and it may also be involved in the reprogramming of differentiated tumor cells into cancer stem cells through the induction of an EMT program. |